Blood Group Typing Market By Product, Test Type, Technique, End-User, Region for 2024-2031

Blood Group Typing Market Valuation - 2024-2031

The increase in voluntary blood donations has led to a higher demand for blood group recognition and cross-matching procedures for transfusion. Thus, the increase in voluntary blood donations surged the growth of market size surpassing USD 2.96 Billion in 2024 to reach the valuation of USD 6.16 Billion by 2031.

The increasing incidence of diseases like cancer, blood disorders, and chronic anemia is driving the need for blood transfusions and, consequently, blood typing. Thus, the rising prevalence of chronic diseases requiring blood transfusions enables the market to grow at aCAGR of 9.60% from 2024 to 2031.

Blood Group Typing Market: Definition/ Overview

Blood group typing is a vital medical procedure that determines a person's blood type by identifying specific antigens on the surface of red blood cells. This process is crucial in various medical applications, such as ensuring compatibility for blood transfusions and organ transplants, as well as managing pregnancies, to prevent hemolytic disease of the newborn, which occurs when the mother's immune system attacks the fetus's red blood cells.

The demand for accurate blood group typing continues to grow, driven by the increasing need for blood transfusions and organ transplantations. The World Health Organization (WHO) reports a significant rise in voluntary blood donations, with an increase of 10.7 million donations between 2008 and 2018, indicating a corresponding rise in blood typing procedures. This rise in demand is further fueled by the growing number of accidents, trauma, and injury cases worldwide. Research indicates that 6 out of 10 trauma-related deaths result from excessive bleeding within the first three hours, underscoring the importance of timely blood transfusions, which require accurate blood group typing.

Advancements in genetic testing and molecular diagnostics are enhancing the accuracy and speed of blood typing procedures, paving the way for more precise and tailored healthcare solutions. As healthcare systems prioritize patient safety and personalized treatment, the demand for reliable blood group typing is expected to rise, further expanding its medical and healthcare applications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How the Technological Advancements in Blood Typing Methods Surge the Growth of Blood Group Typing Market?

Innovations in blood typing technologies, such as molecular typing and automated systems, are enhancing the efficiency and accuracy of blood group typing. A 2020 study published in the journal Transfusion Medicine Reviews found that the adoption of automated blood typing systems in blood banks increased by 35% between 2015 and 2019. Increased awareness among healthcare providers and patients about the critical nature of accurate blood typing is driving market growth. The Joint Commission, which accredits healthcare organizations in the U.S., reported in 2018 that the implementation of patient blood management programs, which include robust pre-transfusion testing, reduced blood product utilization by an average of 12% in participating hospitals.

The rising number of surgical procedures, many of which require blood transfusions, is boosting the demand for blood group typing. The Centers for Disease Control and Prevention (CDC) reported that in 2018, there were 48.3 million surgical and nonsurgical procedures performed in U.S. hospitals, with many requiring blood typing and potential transfusions. The growing focus on prenatal and neonatal care, including blood type compatibility testing between mother and fetus, is driving market growth. According to the National Vital Statistics Reports, there were approximately 3.75 million births in the United States in 2019, each potentially requiring blood typing for both mother and child.

How do the Lack Of Infrastructure in Emerging Countries and the High Cost Of Advanced Blood Typing Technologies Impede the Growth of the Blood Group Testing Market?

The lack of infrastructure for blood group typing, especially in emerging countries, is a significant restraint. According to a 2019 World Health Organization report, only 62% of countries had national blood policies, with lower-middle-income countries having the lowest rate at 48%. The expensive nature of modern blood typing equipment and reagents limits adoption, especially in resource-constrained settings. A 2018 study published in the journal Transfusion Medicine estimated that the cost of implementing a fully automated blood typing system in a medium-sized blood bank could range from $100,000 to $500,000, potentially limiting widespread adoption.

The lack of trained personnel to operate advanced blood typing systems hinders market growth. The American Society for Clinical Pathology's 2018 Vacancy Survey reported a vacancy rate of 10.6% for blood bank technologists/specialists in the United States, indicating a significant shortage of skilled professionals in the field. While manual methods are still widely used, especially in resource-limited settings, they are prone to human error, which can limit trust and adoption. A 2020 meta-analysis published in the journal Transfusion found that the error rate in manual blood typing ranged from 0.05% to 0.8%, depending on the specific technique and setting.

Category-Wise Acumens

How did the Increasing Chronic Disorders and Growing Number of Surgical Procedure Surge the Growth of the ABO Segment?

The ABO segment is dominant in the blood group testing market, driven by the rising prevalence of chronic diseases and the increasing number of surgical procedures requiring blood transfusions. Accurate ABO blood typing is crucial in ensuring compatibility between blood donors and recipients, significantly reducing the risk of adverse reactions during medical procedures. As a result, there has been a notable surge in demand for ABO blood typing tests, which is propelling the growth of this market segment.

Moreover, advancements in medical technology and diagnostic instruments have significantly enhanced the accuracy and efficiency of blood typing systems. The ability to swiftly and accurately determine blood types through automated methods has heightened the demand for ABO blood typing tests. Healthcare professionals prioritize patient safety and the reliability of medical procedures, making ABO testing an indispensable tool in modern healthcare. This growing emphasis on precision and efficiency ensures that the ABO segment will continue to dominate the blood group testing market in the years to come.

How the Extensive Use of Reagents & Kits in Blood Donation and Transfusion Procedure Surge the Growth of Reagents & Kits Segment?

The reagents & kits segment holds a dominant position in the blood group testing market, driven by their extensive use in blood donation and transfusion procedures. These products are essential for accurate blood typing, making them a critical component in ensuring compatibility between donors and recipients, particularly in life-saving situations such as surgeries, trauma care, and organ transplants. As the global demand for blood donations and transfusions continues to rise, the use of reagents & kits in healthcare facilities and blood banks has significantly increased, fueling the segment's growth.

The surge in voluntary blood donations and the expansion of healthcare infrastructure worldwide. With more individuals donating blood, the demand for reliable and efficient blood typing reagents has become paramount. Additionally, reagents are indispensable in determining blood types quickly and accurately, ensuring patient safety during transfusion procedures.

In addition, the segment is poised for continued growth as the adoption of advanced diagnostic technologies accelerates. As healthcare systems increasingly rely on automated and high-throughput instruments for blood typing, the need for specialized reagents & kits to complement these systems is expected to rise, ensuring the segment's strong presence in the market throughout the forecast period.

Country/Region-wise Acumens

How does the Significant Demand for Blood Transfusions Accelerate the Growth of the Blood Group Typing Market in North America?

North America substantially dominates the blood group testing market owing to the high demand for blood transfusions in North America, particularly in the United States. According to the American Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S. The organization also reports that nearly 16 million blood components are transfused each year in the United States.

The increased adoption of automated blood typing systems in North American healthcare facilities is driving market growth. A 2019 survey by the College of American Pathologists reported that 78% of participating laboratories in the U.S. and Canada were using fully or partially automated systems for ABO/Rh typing, up from 65% in 2014.

The favorable reimbursement policies for blood typing procedures and the rising number of regulatory approvals for advanced products are driving market growth in North America. The Centers for Medicare & Medicaid Services (CMS) reported that in 2020, the national average Medicare reimbursement for ABO and Rh blood typing (CPT code 86900) was $7.77, while for antibody screening (CPT code 86850) it was $17.28, providing financial incentives for healthcare providers to perform these tests. Additionally, the U.S. Food and Drug Administration (FDA) approved 12 new or updated blood typing-related products between 2018 and 2020, indicating a growing market for advanced blood typing technologies.

How the Rising Incidence of Chronic Diseases and Increasing Demand for Blood Transfusions Propel the Growth of Blood Group Testing Market in Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the blood group testing market driven by the prevalence of chronic diseases like cancer and kidney disorders is growing in Asia Pacific countries, leading to a higher demand for blood transfusions and typing. According to the World Health Organization (WHO), the number of new cancer cases in the Asia-Pacific region is expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This 30% increase will likely drive up the need for blood typing and transfusions.

Many Asia Pacific countries are investing heavily in healthcare infrastructure and increasing their healthcare spending, which supports the expansion of blood typing services. The Indian government's healthcare expenditure increased from 1.2% of GDP in 2013-14 to 1.8% in 2020-21, according to the Economic Survey 2020-21. This growth in healthcare spending is likely to boost investments in blood typing technologies and services.

There's an increasing awareness about the importance of blood donation in the region, supported by various government and non-government initiatives. In China, the number of voluntary blood donors increased from 12.32 million in 2011 to 15.48 million in 2019, according to data from the National Health Commission of China. This 25% increase in blood donors over eight years indicates a growing need for efficient blood typing services.

Competitive Landscape

The Blood Group Testing Market is a dynamic and competitive industry driven by factors such as increasing healthcare expenditure, growing awareness of blood group compatibility, and advancements in testing technologies. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers, blood banks, and individual consumers.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the blood group typing market include:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche Ltd.
• Grifols, Immucor, Inc.
• Ortho Clinical Diagnostics
• Quotient Limited
• BioMerieux SA
• DiaSorin S.p.A.
• Merck KGaA.

Latest Developments:

• In June 2023, Quotient Limited announced the launch of its ALBA products in Sweden and the Netherlands. The items were also launched in France, Germany, Austria, Hungary, Italy, Greece, Poland, Romania, Luxembourg, and Slovakia.
• In June 2023, Quotient Limited announced an agreement with Transmedic Pte Ltd to distribute ALBA by Quotient and MosaiQ in five Southeast Asian countries: Indonesia, Singapore, Malaysia, Thailand, and Vietnam.
• In May 2023, Bio-Rad Laboratories, Inc. unveiled the IH-500TM NEXT System, a fully automated ID card system designed to address the changing demands and difficulties of the laboratory and healthcare environments.